KR102768284B1 - Jak 패밀리의 키나제의 소분자 억제제 - Google Patents

Jak 패밀리의 키나제의 소분자 억제제 Download PDF

Info

Publication number
KR102768284B1
KR102768284B1 KR1020217000012A KR20217000012A KR102768284B1 KR 102768284 B1 KR102768284 B1 KR 102768284B1 KR 1020217000012 A KR1020217000012 A KR 1020217000012A KR 20217000012 A KR20217000012 A KR 20217000012A KR 102768284 B1 KR102768284 B1 KR 102768284B1
Authority
KR
South Korea
Prior art keywords
diffractogram
delete delete
compound
suspension
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217000012A
Other languages
English (en)
Korean (ko)
Other versions
KR20210021342A (ko
Inventor
필리페 페르난데스
마크 에스. 티치노르
폴 제이. 크라우스주크
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20210021342A publication Critical patent/KR20210021342A/ko
Application granted granted Critical
Publication of KR102768284B1 publication Critical patent/KR102768284B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
KR1020217000012A 2018-06-15 2019-06-14 Jak 패밀리의 키나제의 소분자 억제제 Active KR102768284B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685737P 2018-06-15 2018-06-15
US62/685,737 2018-06-15
US201962846290P 2019-05-10 2019-05-10
US62/846,290 2019-05-10
PCT/IB2019/055005 WO2019239387A1 (en) 2018-06-15 2019-06-14 Small molecule inhibitors of the jak family of kinases

Publications (2)

Publication Number Publication Date
KR20210021342A KR20210021342A (ko) 2021-02-25
KR102768284B1 true KR102768284B1 (ko) 2025-02-13

Family

ID=67766195

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000012A Active KR102768284B1 (ko) 2018-06-15 2019-06-14 Jak 패밀리의 키나제의 소분자 억제제

Country Status (23)

Country Link
US (3) US20200017498A1 (https=)
EP (1) EP3807277A1 (https=)
JP (1) JP2021528391A (https=)
KR (1) KR102768284B1 (https=)
CN (1) CN112313233A (https=)
AU (1) AU2019286641A1 (https=)
BR (1) BR112020024744A2 (https=)
CA (1) CA3101438A1 (https=)
CL (1) CL2020003227A1 (https=)
CO (1) CO2020015396A2 (https=)
CR (1) CR20200603A (https=)
EC (1) ECSP20080817A (https=)
IL (1) IL279314A (https=)
JO (1) JOP20200311A1 (https=)
MA (1) MA52900A (https=)
MX (1) MX2020013688A (https=)
NI (1) NI202000100A (https=)
PE (1) PE20212113A1 (https=)
PH (1) PH12020551984A1 (https=)
SG (1) SG11202011691PA (https=)
TW (1) TW202016110A (https=)
UY (1) UY38262A (https=)
WO (1) WO2019239387A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
BR112023018286A2 (pt) * 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102352462B1 (ko) * 2016-12-16 2022-01-17 얀센 파마슈티카 엔.브이. Jak 패밀리의 키나제의 소분자 억제제

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA67844C2 (uk) 1999-04-23 2004-07-15 Смітклайн Бічам Плс Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MXPA04011865A (es) 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
EP1902029B2 (en) 2005-07-01 2022-02-16 Wyeth LLC Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
JP5567137B2 (ja) 2009-09-03 2014-08-06 ブリストル−マイヤーズ スクイブ カンパニー Ｊａｋ２阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
PE20121336A1 (es) 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2534258B1 (en) 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja) 2014-05-14 2015-11-19 日産化学工業株式会社 ３環性化合物及びｊａｋ阻害剤
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TWI735681B (zh) 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
EP3555064B9 (en) 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045224A1 (en) 2016-12-16 2018-06-21 Basf Se Pesticidal compounds
KR102276022B1 (ko) 2016-12-16 2021-07-13 일라이 릴리 앤드 캄파니 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3528645A1 (en) 2016-12-16 2019-08-28 Société des Produits Nestlé S.A. Oligosaccharides for flavour generation
PL3568396T3 (pl) 2017-01-11 2021-05-31 Leo Pharma A/S Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne
PT3494116T (pt) 2017-01-30 2020-01-28 Astrazeneca Ab Moduladores de recetores de estrogénio
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102352462B1 (ko) * 2016-12-16 2022-01-17 얀센 파마슈티카 엔.브이. Jak 패밀리의 키나제의 소분자 억제제

Also Published As

Publication number Publication date
US20200017498A1 (en) 2020-01-16
US11066406B2 (en) 2021-07-20
EP3807277A1 (en) 2021-04-21
US20210340144A1 (en) 2021-11-04
JP2021528391A (ja) 2021-10-21
CR20200603A (es) 2021-01-20
NI202000100A (es) 2021-06-30
BR112020024744A2 (pt) 2021-03-23
KR20210021342A (ko) 2021-02-25
PH12020551984A1 (en) 2021-08-02
UY38262A (es) 2019-12-31
US20200165250A1 (en) 2020-05-28
IL279314A (en) 2021-01-31
WO2019239387A1 (en) 2019-12-19
JOP20200311A1 (ar) 2020-11-30
MA52900A (fr) 2021-04-21
ECSP20080817A (es) 2021-01-29
CL2020003227A1 (es) 2021-05-14
TW202016110A (zh) 2020-05-01
CA3101438A1 (en) 2019-12-19
PE20212113A1 (es) 2021-11-04
MX2020013688A (es) 2021-02-26
CO2020015396A2 (es) 2021-03-08
US11787807B2 (en) 2023-10-17
AU2019286641A1 (en) 2020-12-10
SG11202011691PA (en) 2020-12-30
CN112313233A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
AU2022204240B2 (en) Small molecule inhibitors of the JAK family of kinases
KR102768284B1 (ko) Jak 패밀리의 키나제의 소분자 억제제
CA3046965C (en) Small molecule inhibitors of the jak family of kinases
HK40008834B (zh) Jak家族激酶的小分子抑制剂
HK40014753B (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
HK40014753A (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
BR112019011968B1 (pt) Inibidores de pequenas moléculas da família jak de quinases
EA037347B1 (ru) Низкомолекулярные ингибиторы киназ семейства jak

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220602

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240319

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241115

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250211

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250211

End annual number: 3

Start annual number: 1

PG1601 Publication of registration